Activating mutations of PI3K lead to persistent activation of the PI3K/AKT/mTOR pathway despite EGFR inhibition and have been shown to confer resistance in gefitinib-sensitive lung cancer cell lines39. This evidence concerns the gene AKT1 and lung carcinoma.